Comprehensive Analysis of Cytochrome p450 Enzymes:
Roles in Drug Metabolism and Drug-Drug Interactions
Mayur Bhamare, Rushikesh Bachhav, Ganesh Sonawane, Sunil Mahajan, Vijayraj Sonawane
Divine College of Pharmacy, Department of Pharmaceutical Quality Assurance, Satana.
*Corresponding Author E-mail: mayurbhamare0404@gmail.com
ABSTRACT:
The superfamily of heme-containing proteins known as cytochrome P450 (CYP) enzymes is essential to the metabolism of many different endogenous and exogenous substances, including medications. Individual differences in CYP enzyme activity have a substantial impact on medication safety and efficacy, which can result in adverse drug reactions (ADRs) and drug-drug interactions (DDIs). The structure, function, and control of CYP enzymes, their involvement in drug metabolism, the mechanisms behind DDIs, and the clinical consequences for pharmacotherapy are all thoroughly examined in this study. It also covers methods for anticipating and controlling DDIs in order to maximise therapeutic results.
KEYWORDS: Drug Metabolism, Enzyme induction, Enzyme inhibition, CYP isoforms, Pharmacokinetics, CYP450 substrates, CYP450 inhibitors, Drug Interaction.
INTRODUCTION:
Medicines undergo phase I metabolism, which is made possible by the cytochrome P450 enzymes. This process converts medicines into more hydrophilic molecules that can be excreted later. These enzymes, which are mostly located in the liver, are also present in other tissues and have an impact on how medications work in the body. Drug response can vary significantly between individuals due to genetic polymorphisms, environmental variables, and concurrent drugs causing variations in CYP enzyme function. The safe and efficient administration of pharmacological treatments depends on an understanding of the function of CYP enzymes in drug metabolism and their connection to DDIs.
THE COMPOSITION AND ROLES OF CYTOCHROME P450 ENZYMES:1-3
Heme-Thiolate proteins, or CYP enzymes, are identified by a highly conserved heme-binding domain. The iron atom-containing heme group is necessary for the catalytic activity of the enzyme.
Heme Group:
The iron atom in the heme group oscillates between the Fe2+ and Fe3+ states, which aids in electron transport and the molecule oxygen's activation.
The active site where substrates bind and undergo oxidation is formed by the protein scaffold.
Membrane Anchor:
The endoplasmic reticulum of hepatocytes is the primary location of several CYP enzymes, which are membrane-bound.
Oxidation: One oxygen atom is inserted into the substrate (RH) during oxidation, whereas the other oxygen atom is reduced to water.
Detoxification:
Detoxification is the process by which lipophilic substances are changed into more hydrophilic metabolites for elimination.
Activation:
The transformation of prodrugs into their active counterparts under certain conditions
PRINCIPAL CYP ISOFORMS ASSOCIATED WITH DRUG METABOLISM:4,5
Drug metabolism is attributed to several CYP isoforms. The most important in terms of therapy are:
Prevalence:
CYP3A4 makes up around 30% of the total CYP content in the liver, making it the most prevalent CYP enzyme.
Substrate Specificity:
Metabolises a variety of medications, such as immunosuppressants, benzodiazepines, and statins.
Rifampicin strongly induces this process, while ketoconazole and grapefruit juice prevent it
Table no.1
|
CYP3A4 |
||
|
Substrate |
Inducer |
Inhibitor |
|
Cyclophosphamide |
Phenytoin |
Ritonavir |
|
Tacrolimus |
Enzalutamide |
Clarithromycin |
|
Ketoconazole |
St. John’s Wort |
Voriconazole |
|
Erythromycin |
Rifampicin |
Chloramphenicol |
|
Amitriptyline |
Efavirenz |
Amiodarone |
|
Citaloperidol |
Pioglitazone |
Cyclosporine |
|
Haloperidol |
Clobazam |
Imatinib |
|
Fentanyl |
Telotristat |
Valproic Acid |
|
Diazepam |
Phenobarbital |
|
|
Verapamil |
Tcagrelor |
|
Genetic Polymorphism:
Defines a broad range of genetic variations that result in distinct metaboliser phenotypes, including extensive, poor, ultrarapid, and intermediate metabolisers.
Substrate Specificity:
Breaks down a lot of opioids, antipsychotics, and antidepressants
Clinical Relevance:
To reduce adverse drug reactions, genetic testing can help determine how much CYP2D6 substrate to take.
Table no.2
|
CYP2D |
||
|
Substrate |
Inducer |
Inhibitor |
|
Imipramine |
Glutethimide |
Fluoxetine |
|
Fluoxetine |
Dexamethasone |
|
|
Paroxetine |
Rifampicin |
Bupropion |
|
Venlafaxine |
Haloperidol |
|
|
Duloxetine |
|
Quinidine |
|
Mirtazapine |
|
|
|
Codeine |
|
Ritonavir |
|
Tramadol |
|
|
|
|
|
Cannabidiol/ Shutter |
|
Oxycodone |
|
|
|
|
|
Terbinafine |
|
propranolol |
|
|
|
|
|
Duloxetine |
|
|
|
|
|
|
|
Methylphenidate |
|
|
|
|
|
|
|
Escitalopram |
|
|
|
|
|
|
|
Sertraline |
Table no.3
|
CYP2C9 |
||
|
Substrate |
Inducer |
Inhibitor |
|
Celecoxib |
Rifampicin |
Miconazole |
|
Ibuprofen |
Secobarbital |
Valproic acid |
|
Piroxicam |
Bosentan |
Sulfathiazole |
|
Diclofenac |
Phenobarbital |
Amiodarone |
|
Phenytoin |
St. John’s Wort |
Fluconazole |
|
Fluvastatin |
|
Metronidazole |
|
Glimepiride |
|
Promethazine |
|
Losartan |
|
Chloramphenicol |
|
Tamoxifen |
|
Zafirlukast |
|
Fluoxetine |
|
|
Genetic Polymorphism:
Enzyme activity is greatly impacted by genetic variations.
Substrate Specificity:
Breaks down oral anticoagulants such as warfarin, certain antidiabetic medications, and nonsteroidal anti-inflammatory medicines (NSAIDs).
Clinical Importance:
Variations in CYP2C9 activity require close observation and dosage modification of substrates such as warfarin
Genetic Polymorphism:
As with CYP2D6, genetic polymorphisms lead to distinct phenotypes for metabolisers.
Substrate Specificity:
DE metabolizes clopidogrel, certain antidepressants, and proton pump inhibitors (PPIs).
Clinical Significance:
Clopidogrel medication to avoid cardiovascular events can be informed by genetic testing for CYP2C19
Table no.4
|
CYP2C19 [9 |
||
|
Substrate |
Inducer |
Inhibitor |
|
Amitriptyline |
Rifampicin |
Fluconazole |
|
Citalopram |
Carbamazepine |
Ticlopidine |
|
Sertraline |
Norethisterone |
Chloramphenicol |
|
Diazepam |
Prednisone |
Felbamate |
|
Primidone |
Aspirin |
Topiramate |
|
Phenytoin |
|
Cimetidine |
|
Omeprazole |
|
Modafinil |
|
Pantoprazole |
|
Isoniazid |
|
Proguanil |
|
|
|
Indomethacin |
|
|
CONTROL OF CYP ENZYME FUNCTION10,11:
Variations in CYP gene genetic polymorphisms can result in varying levels of enzyme activity, from total loss of function to elevated activity. As an illustration:
CYP2D6:
More than 100 allelic variations affect the activity of the enzyme CYP2D6.
CYP2C9:
CYP2C92 and CYP2C93 are common variations that are linked to decreased activity.
The activity of CYP enzymes can be altered by diet, way of life, and exposure to substances in the environment. Important elements consist of:
Dietary components:
Cruciferous veggies cause CYP1A2, but grapefruit juice suppresses CYP3A4.
Smoking:
CYP1A2 activity is induced.
Alcohol Consumption:
CYP2E1 is induced by prolonged alcohol usage.
CYP enzymes can be induced or inhibited by drugs, which can result in DDIs that are clinically relevant. As examples, consider:
CYP3A4 is induced by rifampicin, while numerous CYPs are induced by carbamazepine.
Ketoconazole (inhibits CYP3A4) and fluoxetine (inhibits CYP2D6) are examples of inhibitors
DRUG-DRUG INTERACTION MECHANISMS INCLUDING CYP ENZYMES14:
The same CYP enzyme may be used to metabolise two different medications, which could result in competition for the active site and reduced metabolism for one or both of the pharmaceuticals. For example, fluoxetine increases the plasma levels of CYP2D6 substrates such as metoprolol by inhibiting CYP2D6.
A medication may block a CYP enzyme by attaching to an allosteric location, for example, in addition to directly competing with the enzyme at the active site. One such instance is the CYP1A2 inhibitor fluvoxamine.
The induction of CYP enzymes may decrease the therapeutic efficacy of substrates by increasing their metabolism. For instance, rifampicin stimulates CYP3A4, which decreases the potency of medications such as oral contraceptives
Figure no.2 Mechanisms of Drug-Drug Interactions Involving CYP Enzymes
Clinical Consequences of DDIs Mediated by CYP:16
Drugs’ ability to effectively treat patients can be greatly impacted by DDIs. For instance, St. John’s wort induces CYP3A4, which lowers the effectiveness of cyclosporine and raises the possibility of transplant rejection.
Drugs with increased plasma levels can result from CYP enzyme inhibition, which raises the risk of adverse drug reactions. For example, quinidine’s suppression of CYP2D6 can lead to hazardous doses of tricyclic antidepressants.
Comprehending the function of CYP enzymes in drug metabolism enables personalised medicine strategies, like concurrent medication therapy or dose modifications depending on genetic variations14,15.
METHOD FOR FORECASTING AND HANDLING DDIs17,18:
preclinical research with animal models, recombinant CYP enzymes, and human liver microsomes aids in the prediction of possible DDIs and directs the design of clinical trials.
Patients who are at risk for DDIs can be identified through genetic testing for CYP polymorphisms, which can also help with customised dose plans. For instance, clopidogrel medication can be guided by CYP2C19 variant testing.
DDIs can be managed with the aid of plasma drug level monitoring, especially for medications with limited therapeutic indices. Dosage adjustments depending on plasma levels can guarantee efficacy and avoid harm.
Drug selection and dosage can be influenced by knowledge about the potential for interactions between CYP inducers and inhibitors. For instance, myopathy can be avoided by not using statins and strong CYP3A4 inhibitors at the same time
CURRENT DEVELOPMENT AND UPCOMING PATHS:19,20
Mass spectrometry and high-throughput screening technologies have improved the capacity to detect and characterise CYP-mediated DDIs, resulting in safer medication development and more precise forecasts.
Drug dosage regimen optimisation and DDI prediction are made possible by integrating computational models with experimental data. By taking into account the intricate relationships that exist throughout biological systems, systems pharmacology techniques enhance our knowledge of CYP-mediated metabolism.
Research on the creation of medications with a lower risk of CYP-mediated DDIs is also ongoing. This involves creating prodrugs with different metabolic routes or ones that are triggered by particular CYP enzymes.
Drug metabolism depends heavily on cytochrome P450 enzymes, which are also essential for comprehending drug-drug interactions. Drug safety and efficacy are greatly impacted by the genetic, environmental, and pharmacological variations in CYP enzyme activity. The prediction and management of CYP-mediated DDIs are becoming increasingly accurate thanks to developments in pharmacogenetics, analytical methods, and computer modelling, which open the door to more individualised and successful medication. Subsequent investigations ought to concentrate on clarifying the intricate relationships among the CYP enzyme system and devising approaches to reduce the likelihood of unfavourable medication reactions while enhancing treatment results.
NOMENCLATURE:
DDIs: Drug-drug interactions
CYP: Cytochrome P450
ADRs: Adverse drug reactions
REFERANCE:
1. Inaba T, Kovacs PB. Cytochrome P450 enzymes and drug metabolism. CMAJ. 2010; 182(5):523-8.
2. Guengerich FP. Cytochrome P450 and chemical toxicology. Chem Res Toxicol. 2008; 21(1):70-83.
3. Zhou SF, Liu JP, Choubey B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev. 2009; 41(2):89-295.
4. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov. 2005; 4(10):825-33.
5. Rendic S, Di Carlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev. 1997; 29(1-2):413-580.
6. Guengerich FP. Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. Chem Res Toxicol. 2001; 14(6):611-50.
7. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013; 138(1):103-41.
8. Zanger UM, Klein K. Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): Advances and future directions. Front Genet. 2013; 4:24.
9. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer. 2006; 6(12): 947-60.
10. Guengerich FP. Cytochrome P450 and chemical toxicity. Chem Biol Interact. 2004; 147(3):53-67.
11. Wilkinson GR. Drug metabolism and variability among patients in drug response. N Engl J Med. 2005; 352(21): 2211-21.
12. Rodrigues AD. Drug-drug interactions. Pharmacokinetic and pharmacodynamic drug-drug interactions. Clin Pharmacokinet. 1999; 36(1): 59-73.
13. Evans WE, Relling MV. Pharmacogenomics: Translating functional genomics into rational therapeutics. Science. 1999; 286(5439): 487-91.
14. Bhutani KK, Gohil VM. Natural products drug discovery research in India: Status and appraisal. Indian J Exp Biol. 2010; 48(3): 199-207.
15. Burk O, Wojnowski L. Cytochrome P450 3A and its regulation. Naunyn Schmiedebergs Arch Pharmacol. 2004; 369(1): 105-24.
16. Crettol S, Petrovic N, Murray M. Pharmacogenetics of phase I and phase II drug metabolism. Curr Pharm Des. 2010; 16(2): 204-19.
17. Shou M, Korzekwa KR, Crespi CL, Gonzalez FJ, Gelboin HV, Waxman DJ. The role of specific human cytochrome P450 enzymes in the oxidative metabolism of paclitaxel (Taxol). Drug Metab Dispos. 1997; 25(12): 1311-9.
18. Murray GI. The role of cytochrome P450 in drug resistance. Curr Opin Pharmacol. 2006; 6(4): 378-89.
19. Zanger UM, Turpeinen M, Klein K, Schwab M. Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem. 2008; 392(6): 1093-108.
20. Ma Q, Lu AY. Origins of individual variability in P4501A induction. Chem Res Toxicol. 2003; 16(3): 249-60.
21. Hudlicky T. Introduction to enzymes in synthesis. Chemical reviews. 2011 Jul 13; 111(7): 3995-7.
22. Moderation of the Plasma Chemistry and Hematological Indices of Normal and Salt-loaded Rats by an Aqueous Extract of the Rhizomes of Sansevieria Liberica: Implications for the Management of Hypertension and Associated Complications. Asian J. Pharm. Res. 2013; 3(3): 134-140.
23. Nandhini S, Radha R , Vadivu R. Docking of Hematoporphyrin on Various Anticancer Drugs Targeting Enzymes. Asian J. Pharm. Res. 2016; 6(3): 123-130.
24. Mayur S. Jain, Shashikant D. Barhate, Bhushan P. Gayakwad, Prafull P. Patil. Olaparib is an inhibitor of poly (ADP-Ribose) polymerase (PARP) Enzymes: A Review. Asian J. Pharm. Res. 2018; 8(2): 110-112.
25. Sandip S. Kshirsager, Dr. Siraj N. Shaikh, Narendra B. Patil, Ketan B. Patil. Novel Molecule of Protein Tyrosine Kinase Enzyme Inhibitor in Treatment of Breast Cancer: Neratinib Maleate. Asian J. Res. Pharm. Sci. 2020; 10(2):100-102.
26. Sarika V. Khandbahale, Kanchan R. Pagar, Rupali. V. Khankari. Introduction to Enzymes. Asian J. Res. Pharm. Sci. 2019; 9(2): 123-130.
27. I.E. Otuokere. Molecular Mechanics Potential Energy Function of Angiotensin-Converting Enzyme (ACE) inhibitor, Lisinopril. Asian J. Res. Pharm. Sci. 2014; 4(3): 118-124.
28. Vaishali Vijay Pagar, Mitesh P. Sonawane, Parag D. Kothawade, Pratibha K. Pagar, Shamal S. Patil. Formulation Development and Evaluation of Ubidecarenone Chewable Tablet. Asian Journal of Research in Pharmaceutical Sciences. Sci. 2024; 14(1): 6-0.
29. Abhijit Ray. Application of Lipase in Industry. Asian J. Pharm. Tech. 2012; 2(2): 33-37.
30. M. Seenuvasan, N. Balaji, M. Anil Kumar. Review on Enzyme Loaded Magnetic Nanoparticles. Asian J. Pharm. Tech. 2013;3(4): 200-208.
31. Wajid Ahmad, Rihan Jawed, Irfan Khan, Rizwan Khallel, Danish Hakam. A Review on Poly (ADP-ribose) Polymerase (PARP) - An Enzyme that Share the ability to Catalyze the Transfer of ADP-Ribose to Target Proteins. Asian Journal of Pharmacy and Technology. 2023; 13(3):223-8.
32. Soram Ibomcha Singh, Shashi Prabha. Synthesis, Identification of Some P-Chiral Organic Phosphoramidates and Their Inhibitory Action towards Enzymes. Asian J. Research Chem. 2009; 2(4): 523-525.
33. Yatri R Shah, Dhrubo Jyoti Sen, CN Patel. Biochemical Role of Cytochrome P450 Enzymes In-Vivo. Asian J. Research Chem. 2010; 3(2): 243-248.
34. Ubani Chibuike Samuel, Joshua Parker Elijah. Biochemical Assessment of Kerosene Contaminated Diet on the Liver Enzyme Markers of Albino Rats. Asian J. Research Chem. 2010; 3(3): 795-800.
35. Anna Pratima Nikalje, Amogh C. Tathe, Mangesh S. Ghodke. Biocatalysis: A Brief Review. Asian J. Research Chem. 2011; 4(9): 1355-1360.
|
Received on 07.01.2025 Revised on 09.03.2025 Accepted on 01.05.2025 Published on 10.04.2026 Available online from April 13, 2026 Asian J. Res. Pharm. Sci. 2026; 16(2):126-130. DOI: 10.52711/2231-5659.2026.00020 ©Asian Pharma Press All Right Reserved
|
|
|
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License. |
|